Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Sells $591,758.52 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts sold 29,266 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the sale, the chief executive officer now directly owns 260,721 shares of the company’s stock, valued at approximately $5,271,778.62. This represents a 10.09 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $21.25 on Thursday. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33. The business’s 50-day moving average price is $24.34 and its two-hundred day moving average price is $24.88. The company has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the prior year, the company earned ($0.72) EPS. On average, equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Institutional Investors Weigh In On Denali Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its stake in Denali Therapeutics by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 194,859 shares of the company’s stock valued at $4,525,000 after buying an additional 22,900 shares during the last quarter. TD Asset Management Inc lifted its holdings in shares of Denali Therapeutics by 4.5% during the second quarter. TD Asset Management Inc now owns 179,152 shares of the company’s stock worth $4,160,000 after buying an additional 7,766 shares during the last quarter. Arizona State Retirement System increased its position in Denali Therapeutics by 9.0% during the second quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock worth $769,000 after acquiring an additional 2,730 shares during the period. American Century Companies Inc. raised its stake in Denali Therapeutics by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 522,594 shares of the company’s stock valued at $12,135,000 after purchasing an additional 63,058 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Denali Therapeutics by 6.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock worth $32,913,000 after purchasing an additional 84,522 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DNLI. Baird R W raised Denali Therapeutics to a “strong-buy” rating in a report on Tuesday. Robert W. Baird initiated coverage on Denali Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $31.00 price objective for the company. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Finally, JPMorgan Chase & Co. dropped their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.91.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.